Watch 6:00
Why the FDA approved a controversial Alzheimer’s drug
The FDA on Monday approved the first new drug to treat Alzheimer's disease in nearly two decades. Federal health officials said it may help slow the brain-destroying disease's progression, but the approval goes against the agency's independent advisers who said…
How to spot deceptive drug injury ads like the ones Facebook just disabled
Some ads can be more than misleading – they can put your health at risk.
Watch 8:01
What Okla. judgment against Johnson & Johnson means for opioid accountability
An Oklahoma judge delivered a $572 million judgment against pharmaceutical giant Johnson & Johnson in the first major legal decision to go against a drugmaker for its role in the opioid crisis. The judge found the company’s marketing practices helped…
Nonprofit drug maker produces TB antibiotic after private companies wouldn’t
The new antibiotic, called pretomanid and developed by the nonprofit TB Alliance, achieved a 90 percent success rate among patients with drug-resistant TB.
Fake pharmaceuticals are a multi-billion dollar problem around the world. Made and packaged to look like the real deal, these phonies may contain a fraction of the active ingredients or none at all. these fake drugs can have serious consequences…
When prescribing medications, caring for children poses a particular challenge. They’re not just little adults. Their still-developing brains and bodies metabolize drugs differently, and what works for grown-ups can yield radically different — and sometimes dangerous — results in kids.
When Australian biotech firm Innate Immunotherapeutics needed to raise money last summer, it offered a sweetheart deal to “sophisticated U.S. investors.” One of them was Rep. Tom Price.
Trump's nominee to be secretary of health and human services, Rep. Tom Price, could have conflicts of his own.
After news broke that the price of EpiPen injectors has skyrocketed, the allergy medicine’s maker, Mylan, announced its intention to offer a generic version of the product, to be sold at half the market price of the original. The New…
Additional Support Provided By:
